Drug-induced renal failure: a focus on tubulointerstitial disease.

Clin Chim Acta

Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA.

Published: January 2005

Therapeutic agents induce acute renal failure (ARF) by promoting various types of injury to the kidney. Acute interstitial nephritis (AIN) develops from medications that incite an allergic reaction, leading to interstitial inflammation and tubular damage. Acute tubular necrosis (ATN) is a dose-dependent process that develops from direct toxicity on tubular epithelia, typically in the absence of inflammation. Additional, less common patterns of drug-induced renal injury include osmotic nephropathy, crystal nephropathy, and acute nephrocalcinosis. This review focuses on the multitude of patterns of drug-induced renal failure due to tubulointerstitial disease.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cccn.2004.09.005DOI Listing

Publication Analysis

Top Keywords

drug-induced renal
12
renal failure
12
tubulointerstitial disease
8
patterns drug-induced
8
failure focus
4
focus tubulointerstitial
4
disease therapeutic
4
therapeutic agents
4
agents induce
4
acute
4

Similar Publications

Background: Turmeric and boswellia supplements have gained popularity for their anti-inflammatory and antioxidant properties. It is important to critically assess the safety of such supplements for prolonged use.

Objectives: To assess the safety and tolerability of turmeric-boswellia-sesame oil formulation (TBSF) in healthy human volunteers.

View Article and Find Full Text PDF

Unlabelled: Despite the fact that canagliflozin (Cana), a sodium-glucose cotransporter 2 inhibitor, is an anti-diabetic medication with additional effects on the kidney, there is limited experimental data to deliberate its hepato-reno-protective potentiality. Acetaminophen (APAP) overdose remains one of the prominent contributors to hepato-renal damage.

Aim: Our study assessed the novel effect of Cana against APAP-induced toxicities.

View Article and Find Full Text PDF

Incidence and risk factors of Vancomycin-induced thrombocytopenia: a six-year real-world study.

BMC Infect Dis

January 2025

Department of Pharmacy, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application Beijing Hospital, Beijing, 100730, P.R. China.

Objectives: Drug-induced thrombocytopenia has been reported for numerous drugs. Vancomycin-induced thrombocytopenia (VIT) is infrequently and often under-recognized. VIT can lead to the serious consequences of some life-threatening bleeding, especially in high-risk population.

View Article and Find Full Text PDF

Introduction: Lung cancer ranks among the foremost causes of mortality associated with cancer. Ensartinib is a highly effective oral anaplastic lymphoma kinase (ALK) inhibitor utilized in the treatment of ALK-positive lung adenocarcinoma. This report presents a case of acute renal failure attributed to the administration of ensartinib.

View Article and Find Full Text PDF

Tacrolimus-induced thrombotic microangiopathy (TMA) after heart and lung transplantation successfully treated with eculizumab.

Transpl Immunol

December 2024

Pulmonary, Critical Care and Cardiothoracic Surgery, Northwell Health Systems, 300 Community Dr, Manhasset, NY 11030, United States of America.

Introduction: Tacrolimus-induced thrombotic microangiopathy (TMA) causing acute kidney injury (AKI) without systemic features is a rare entity, particularly after non-renal solid organ transplantation.

Case Report: We describe the case of a patient with AKI after combined heart and lung transplantation. Renal biopsy revealed acute thrombotic microangiopathy which ultimately prompted initiation of eculizumab, a monoclonal antibody targeted against complement C5, with subsequent recovery in renal function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!